Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Mar;51(3):797-802.
doi: 10.2337/diabetes.51.3.797.

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

Adam B Mayerson  1 , Ripudaman S Hundal, Sylvie Dufour, Vincent Lebon, Douglas Befroy, Gary W Cline, Staffan Enocksson, Silvio E Inzucchi, Gerald I Shulman, Kitt F Petersen
Affiliations

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

Adam B Mayerson et al. Diabetes. 2002 Mar.

Abstract

We examined the effect of three months of rosiglitazone treatment (4 mg b.i.d.) on whole-body insulin sensitivity and in vivo peripheral adipocyte insulin sensitivity as assessed by glycerol release in microdialysis from subcutaneous fat during a two-step (20 and 120 mU.m(-2).min(-1)) hyperinsulinemic-euglycemic clamp in nine type 2 diabetic subjects. In addition, the effects of rosiglitazone on liver and muscle triglyceride content were assessed by (1)H-nuclear magnetic resonance spectroscopy. Rosiglitazone treatment resulted in a 68% (P < 0.002) and a 20% (P < 0.016) improvement in insulin-stimulated glucose metabolism during the low- and high- dosage-insulin clamps, respectively, which was associated with approximately 40% reductions in plasma fatty acid concentration (P < 0.05) and hepatic triglyceride content (P < 0.05). These changes were associated with a 39% increase in extramyocellular lipid content (P < 0.05) and a 52% increase in the sensitivity of peripheral adipocytes to the inhibitory effects of insulin on lipolysis (P = 0.04). In conclusion, these results support the hypothesis that thiazolidinediones enhance insulin sensitivity in patients with type 2 diabetes by promoting increased insulin sensitivity in peripheral adipocytes, which results in lower plasma fatty acid concentrations and a redistribution of intracellular lipid from insulin responsive organs into peripheral adipocytes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plasma insulin concentrations during the two step hyperinsulinemic-euglycemic clamp before and after rosiglitazone.
Figure 2
Figure 2
Effects of three months of rosiglitazone treatment on insulin suppression of peripheral adipocyte lipolysis during the two-step hyperinsulinemic-euglycemic clamp.
Figure 3
Figure 3
Effects of three months of rosiglitazone treatment on hepatic triglyceride, intramyocellular triglyceride (IMCL) and extramyocellular triglyceride (EMCL) content.
See this image and copyright information in PMC

References

    1. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med. 1999;16:179–192. - PubMed
    1. Tontonoz P, Hu E, Spiegelman BM. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Devel. 1995;5:571–576. - PubMed
    1. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Valiquett TR, Shulman GI. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:176–185. - PubMed
    1. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998;338:867–872. - PubMed
    1. Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI. Mechanism of troglitazone action in type 2 diabetes. Diabetes. 2000;49:827–831. - PubMed

Publication types

MeSH terms